Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 1:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Denosumab Placebo Clear all
Completed Phase 3 Interventional Results available

Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

NCT03292146
View directory record Official record
Conditions
Bone Density, Bone Loss, Anorexia Nervosa, Eating Disorder, Atypical Anorexia Nervosa
Interventions
Denosumab 60 MG [Prolia], Placebo Injection, Alendronate 70Mg Tab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 2 Interventional Results available

RANKL Inhibition and Mammographic Breast Density

NCT04067726
View directory record Official record
Conditions
Dense Breasts
Interventions
Denosumab, Placebo, Calcium, Vitamin D3, Core needle biopsy, Blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Osteoclast Inhibition and Bone Formation

NCT02554695
View directory record Official record
Conditions
Bone Loss, Aging
Interventions
placebo, denosumab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
25 Years to 80 Years · Female only
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis

NCT03164928
View directory record Official record
Conditions
Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With, Glucocorticoid-induced Osteoporosis
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
5 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Wilmington, Delaware • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

NCT00925600
View directory record Official record
Conditions
Cancer, Cataract, Low Bone Mineral Density, Osteopenia, Osteoporosis, Prostate Cancer
Interventions
Denosumab, Placebo
Biological
Lead sponsor
Amgen
Industry
Eligibility
30 Years to 120 Years · Male only
Enrollment
769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
52
States / cities
Anaheim, California • Laguna Hills, California • Murrieta, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 2 Interventional

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

NCT04232657
View directory record Official record
Conditions
Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
Interventions
Romosozumab, Denosumab, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 4 Interventional Results available

Denosumab in Primary Hyperparathyroidism

NCT01558115
View directory record Official record
Conditions
Primary Hyperparathyroidism
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
40 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

NCT01345019
View directory record Official record
Conditions
Cancer, Hematologic Malignancies, Multiple Myeloma, Oncology, Bone Metastases, Multiple Myeloma Bone Lesions
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Placebo to zoledronic acid, Denosumab (for the open-label treatment phase)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
1,718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
79
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 21, 2026, 1:15 AM EDT
Recruiting Phase 4 Interventional

Preserving Geriatric Muscle With an Osteoporosis Medication

NCT06118905
View directory record Official record
Conditions
Osteoporosis
Interventions
Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion
Drug
Lead sponsor
Chrissy Kistler
Other
Eligibility
65 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Not listed Phase 4 Interventional

Denosumab Administration After Spinal Cord Injury

NCT01983475
View directory record Official record
Conditions
Osteoporosis, Spinal Cord Injury
Interventions
Denosumab, Placebo (identical Denosumab volume of normal saline)
Drug
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 8, 2019 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 4 Interventional

Muscle Impact of Treating Osteoporosis

NCT05666310
View directory record Official record
Conditions
Sarcopenia, Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Denosumab Placebo, Zoledronic Acid Placebo
Drug · Other
Lead sponsor
Nami Safai Haeri
Other
Eligibility
65 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Denosumab for Type 1 Diabetes

NCT06524960
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Denosumab, Placebo
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Birmingham, Alabama • Duarte, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Preventing Osteoporosis Using Denosumab

NCT02753283
View directory record Official record
Conditions
Osteoporosis, Postmenopausal, Osteoporosis, Osteoporotic Fractures
Interventions
denosumab, Placebo, Calcium and Vitamin D
Drug · Dietary Supplement
Lead sponsor
Susan L. Greenspan
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 4 Interventional

The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury

NCT03029442
View directory record Official record
Conditions
Secondary Osteoporosis, Spinal Cord Injury
Interventions
Denosumab (Prolia), Placebo (normal saline)
Drug · Other
Lead sponsor
James J. Peters Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
2
States / cities
West Orange, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 3 Interventional Results available

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
93
States / cities
Birmingham, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 21, 2026, 1:15 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation

NCT04711109
View directory record Official record
Conditions
BRCA1 Mutation, Breast Cancer, Breast Diseases, Breast Neoplasms, Breast Carcinoma, Neoplasms
Interventions
Denosumab, Placebo, Quality-of-Life Assessment
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
25 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
47
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Results available

The Effects of 12-months of Denosumab on Bone Density in Prevalent Kidney Transplant Recipients

NCT03960554
View directory record Official record
Conditions
Osteoporosis, Renal Osteodystrophy, Kidney Transplant; Complications
Interventions
Denosumab Inj 60 mg/ml, Placebo
Drug · Other
Lead sponsor
Thomas Nickolas, MD MS
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Chicago, Illinois • Evanston, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis

NCT01575834
View directory record Official record
Conditions
Postmenopausal Osteoporosis
Interventions
Romosozumab, Placebo, Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years to 90 Years · Female only
Enrollment
7,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
25
States / cities
Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids

NCT01575873
View directory record Official record
Conditions
Steroid-induced Osteopor, Glucocorticoid-induced Ostepor
Interventions
Denosumab, Placebo for risendronate, Risendronate, Placebo for denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Sacramento, California • Lakewood, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2018 · Synced Oct 21, 2026, 1:15 AM EDT
Terminated Phase 2 Interventional Results available

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

NCT03457818
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Osteoporosis
Interventions
Denosumab 60 mg/ml [Prolia], Placebo
Drug · Other
Lead sponsor
Mishaela Rubin
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Denosumab to Prevent High-Turnover Bone Loss After Bariatric Surgery

NCT04087096
View directory record Official record
Conditions
Bariatric Surgery Candidate, Bone Loss
Interventions
Denosumab, Placebo, Zoledronic Acid
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
25 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis

NCT01732770
View directory record Official record
Conditions
Post Menopausal Osteoporosis
Interventions
Denosumab, Zoledronic Acid, Placebo to Denosumab, Placebo to Zoledronic Acid
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
55 Years and older · Female only
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
Santa Monica, California • Lakewood, Colorado • Longmont, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 21, 2026, 1:15 AM EDT
Completed Phase 2 Interventional Results available

Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

NCT01951586
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Denosumab, Zoledronic acid, Placebo to Denosumab, Standard Chemotherapy, Placebo to Zoledronic Acid
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
18
States / cities
Goodyear, Arizona • Anaheim, California • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 21, 2026, 1:15 AM EDT